Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about AbbVie Inc.
AbbVie Inc. News
AbbVie Inc. Quantitative Score
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. Earnings & Revenue
AbbVie Inc. Financials
Table Compare
Compare ABBV metrics with: | |||
|---|---|---|---|
Earnings & Growth | ABBV | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ABBV | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ABBV | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ABBV | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
AbbVie Inc. Income
AbbVie Inc. Balance Sheet
AbbVie Inc. Cash Flow
AbbVie Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
AbbVie Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 6.2900 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-02-14 | 1.64 | Quarterly |
| 2024-11-15 | 1.55 | Quarterly |
| 2024-08-15 | 1.55 | Quarterly |
| 2024-05-15 | 1.55 | Quarterly |
| 2024-02-15 | 1.55 | Quarterly |
AbbVie Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
AbbVie Inc. Executives
| Name | Role |
|---|---|
| Mr. Richard A. Gonzalez | Executive Chairman |
| Mr. Robert A. Michael CPA | Chief Executive Officer & Director |
| Mr. Jeffrey Ryan Stewart | Executive Vice President & Chief Commercial Officer |
| Dr. Azita Saleki-Gerhardt Ph.D. | Executive Vice President & Chief Operating Officer |
| Mr. Scott T. Reents | Executive Vice President & Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Richard A. Gonzalez | Executive Chairman | Male | 1954 | 7.19M |
| Mr. Robert A. Michael CPA | Chief Executive Officer & Director | Male | 1970 | 4.62M |
| Mr. Jeffrey Ryan Stewart | Executive Vice President & Chief Commercial Officer | Male | 1969 | 4.32M |
| Dr. Azita Saleki-Gerhardt Ph.D. | Executive Vice President & Chief Operating Officer | 1963 | 3.51M | |
| Mr. Scott T. Reents | Executive Vice President & Chief Financial Officer | Male | 1967 | 3.13M |
AbbVie Inc. Insider Trades
| Date | 31 Dec |
| Name | Alpern Robert J |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 42 |
| Date | 31 Dec |
| Name | Quaggin Susan E |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 84 |
| Date | 31 Dec |
| Name | RAPP EDWARD J |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 182 |
| Date | 16 Dec |
| Name | Buckbee Kevin K |
| Role | SVP, CONTROLLER |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 1800 |
| Date | 16 Dec |
| Name | Buckbee Kevin K |
| Role | SVP, CONTROLLER |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1800 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 31 Dec | Alpern Robert J | Director | Acquired | A-Award | 42 |
| 31 Dec | Quaggin Susan E | Director | Acquired | A-Award | 84 |
| 31 Dec | RAPP EDWARD J | Director | Acquired | A-Award | 182 |
| 16 Dec | Buckbee Kevin K | SVP, CONTROLLER | Acquired | M-Exempt | 1800 |
| 16 Dec | Buckbee Kevin K | SVP, CONTROLLER | Disposed | S-Sale | 1800 |